Novartis Drug Helps Broader Group of Rare-Disease Patients

(Bloomberg) -- Novartis AG’s Zolgensma, a gene therapy under review for treating children with a rare inherited disease that typically kills before the age of 2, also appears promising for a broade...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.